Editas Medicine (EDIT) Receives a Hold from RBC Capital
I'm PortAI, I can summarize articles.
RBC Capital analyst Luca Issi has maintained a Hold rating on Editas Medicine (EDIT) with a price target of $4.00, while the stock closed at $2.52. The analyst consensus for Editas is also a Hold, with a price target of $3.95, indicating a potential upside of 56.75%. Barclays has similarly rated the stock as Hold with a $3.00 price target. Issi has an average return of 6.7% and a success rate of 41.16% on his recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments